Franklin Genomic Advancements ETF (HELX)
Franklin Genomic Advancements ETF operates in the Asset Management industry of the Financial Services sector, headquartered in San Mateo, CA, US. The stock last traded at $44.30, up 0.03% on the session, giving a market capitalisation of $33.2M. Its beta of 0.98 implies it has historically moved less than the broad market.
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Franklin Genomic Advancements ETF is most often compared with the following Financial Services names: